Nothing Special   »   [go: up one dir, main page]

RU2004131870A - Фармацевтический препарат, содержащий оксикодон и налоксон - Google Patents

Фармацевтический препарат, содержащий оксикодон и налоксон Download PDF

Info

Publication number
RU2004131870A
RU2004131870A RU2004131870/15A RU2004131870A RU2004131870A RU 2004131870 A RU2004131870 A RU 2004131870A RU 2004131870/15 A RU2004131870/15 A RU 2004131870/15A RU 2004131870 A RU2004131870 A RU 2004131870A RU 2004131870 A RU2004131870 A RU 2004131870A
Authority
RU
Russia
Prior art keywords
drug according
naloxone
oxycodone
contained
preparation
Prior art date
Application number
RU2004131870/15A
Other languages
English (en)
Other versions
RU2295344C2 (ru
Inventor
Бианка БРЕГМАНН (DE)
Бианка БРЕГМАНН
Зилке МЮХЛАУ (DE)
Зилке МЮХЛАУ
Кристоф ШПИТЦЛЕЙ (DE)
Кристоф ШПИТЦЛЕЙ
Original Assignee
Еуро-Селтик С.А. (Lu)
Еуро-Селтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2004131870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10215131A external-priority patent/DE10215131A1/de
Priority claimed from DE10215067A external-priority patent/DE10215067A1/de
Application filed by Еуро-Селтик С.А. (Lu), Еуро-Селтик С.А. filed Critical Еуро-Селтик С.А. (Lu)
Publication of RU2004131870A publication Critical patent/RU2004131870A/ru
Application granted granted Critical
Publication of RU2295344C2 publication Critical patent/RU2295344C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (30)

1. Стабильный при хранении фармацевтический препарат, содержащий оксикодон и налоксон в практически ненабухающей диффузионной матрице, включающей этилцеллюлозу, характеризующийся тем, что активные соединения высвобождаются из препарата длительно, неизменно и независимо друг от друга.
2. Препарат по п.1, отличающийся тем, что оксикодон и/или налоксон содержатся в виде их фармацевтически приемлемых производных с такой же активностью, например, свободных оснований или солей.
3. Препарат по п.2, отличающийся тем, что оксикодон и/или налоксон содержатся в виде их гидрохлорида, сульфата, бисульфата, тартрата, нитрата, цитрата, битартрата, фосфата, малата, малеата, гидробромида, гидроиодида, фумарата или сукцината.
4. Препарат по одному из предыдущих пунктов, отличающийся тем, что оксикодон содержится в избытке по отношению к налоксону, содержащемуся в единичной дозе.
5. Препарат по п.1, отличающийся тем, что налоксон содержится в количестве от 1 до 50 мг.
6. Препарат по п.1, отличающийся тем, что оксикодон содержится в количестве от 10 до 150 мг, предпочтительно от 10 до 80 мг.
7. Препарат по п.1, отличающийся тем, что оксикодон и налоксон содержатся в весовом отношении, равном максимально 25:1, предпочтительно максимально 20:1, 15:1, особенно предпочтительно 5:1, 4:1, 3:1, 2:1 или 1:1.
8. Препарат по п.1, отличающийся тем, что он содержит практически не набухающую и не разрушающуюся диффузионную матрицу.
9. Препарат по п.1, отличающийся тем, что диффузионная матрица содержит, по меньшей мере, этилцеллюлозу и, по меньшей мере, один жирный спирт в качестве компонентов, которые существенно влияют на характер высвобождения активных соединений.
10. Препарат по п.1, отличающийся тем, что препарат содержит обычные наполнители и добавки, особенно смазывающие агенты, агенты, облегчающие текучесть, пластификаторы.
11. Препарат по п.10, отличающийся тем, что он содержит в качестве смазывающего агента стеарат магния, стеарат кальция, и/или лаурат кальция, и/или жирные кислоты, предпочтительно, стеариновую кислоту.
12. Препарат по п.10, отличающийся тем, что в качестве добавок, способствующих текучести, он содержит высокодисперсную двуокись кремния, предпочтительно Aerosil®, тальк, кукурузный крахмал, окись магния и стеарат магния и/или кальция.
13. Стабильный при хранении фармацевтический препарат, содержащий оксикодон и налоксон в практически ненабухающей диффузионной матрице, характеризующийся тем, что характеристики высвобождения матрицы зависят от этилцеллюлозы и, по меньшей мере, одного жирного спирта, и препарат содержит оксикодон и налоксон в весовом отношении максимально 25:1, предпочтительно максимально 20:1, 15:1, особенно предпочтительно 5:1, 4:1, 3:1, 2:1 или 1:1.
14. Препарат по п.13, отличающийся тем, что оксикодон и налоксон содержатся в виде их фармацевтически приемлемых производных с равной активностью, например свободных оснований или солей.
15. Препарат по п.14, отличающийся тем, что оксикодон и налоксон содержатся в виде гидрохлорида, сульфата, бисульфата, тартрата, нитрата, цитрата, битартрата, фосфата, малата, малеата, гидробромида, гидроиодида, фумарата или сукцината.
16. Препарат по п.13, отличающийся тем, что оксикодон содержится в единичной дозе в избытке по отношению к налоксону.
17. Препарат по п.13, отличающийся тем, что налоксон содержится в количестве от 1 до 50 мг.
18. Препарат по п.13, отличающийся тем, что оксикодон содержится в количестве от 10 до 150 мг, предпочтительно от 10 до 80 мг.
19. Препарат по п.13, отличающийся тем, что препарат содержит практически не набухающую и не разрушающуюся диффузионную матрицу.
20. Препарат по п.19, отличающийся тем, что диффузионная матрица включает, по меньшей мере, этилцеллюлозу и, по меньшей мере, один жирный спирт в качестве компонентов, которые существенно влияют на характер высвобождения активных соединений.
21. Препарат по п.13, отличающийся тем, что жирные спирты включают лауриловый, миристиловый, стеариловый, цетостеа-риловый и/или цетиловый спирты, особенно предпочтительно стеариловый спирт.
22. Препарат по п.13, отличающийся тем, что он содержит обычные наполнители и добавки, особенно, смазывающие агенты, агенты, способствующие текучести, пластификаторы.
23. Препарат по п.22, отличающийся тем, что он в качестве смазывающих агентов содержит стеарат магния, стеарат кальция и/или лаурат кальция и/или жирные кислоты, предпочтительно стеариновую кислоту.
24. Препарат по п.22, отличающийся тем, что он содержит в качестве добавок, способствующих текучести, высокодисперсную двуокись кремния, предпочтительно Aerosil®, тальк, кукурузный крахмал, окись магния и стеарат магния и/или кальция.
25. Препарат по п.1 или 13, отличающийся тем, что вместо этилцеллюлозы он содержит коммерчески доступные полимерные смеси, которые включают этилцеллюлозу, предпочтительно Surelease® E-7-7050.
26. Препарат по п.1 или 13, характеризующийся тем, что он получен для орального, назального, ректального введения или для введения путем ингаляции.
27. Препарат по п.1 или 13, отличающийся тем, что он является таблеткой, пилюлей, капсулой, гранулой или порошком.
28. Препарат по п.1 или 13, отличающийся тем, что он или его предшественник получены методом гранулирования с укрупнением или измельчением.
29. Препарат по п.1 или 13, отличающийся тем, что он или его предшественники получены методом экструзии.
30. Препарат по п.1 или 13, отличающийся тем, что он может храниться в течение, по меньшей мере, двух лет в стандартных условиях при 60%-ной относительной влажности и температуре 25°С.
RU2004131870/15A 2002-04-05 2003-04-04 Фармацевтический препарат, содержащий оксикодон и налоксон RU2295344C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10215131A DE10215131A1 (de) 2002-04-05 2002-04-05 Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
DE10215131.8 2002-04-05
DE10215067.2 2002-04-05
DE10215067A DE10215067A1 (de) 2002-04-05 2002-04-05 Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst

Publications (2)

Publication Number Publication Date
RU2004131870A true RU2004131870A (ru) 2005-05-27
RU2295344C2 RU2295344C2 (ru) 2007-03-20

Family

ID=28676052

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2004131870/15A RU2295344C2 (ru) 2002-04-05 2003-04-04 Фармацевтический препарат, содержащий оксикодон и налоксон
RU2004130845/15A RU2297225C2 (ru) 2002-04-05 2003-04-04 Матрица, обеспечивающая пролонгированное, инвариантное и независимое высвобождение активных соединений
RU2006128796/15A RU2342935C2 (ru) 2002-04-05 2006-08-08 Фармацевтическая композиция для лечения вызываемых опиоидами побочных эффектов и идиопатических синдромов

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2004130845/15A RU2297225C2 (ru) 2002-04-05 2003-04-04 Матрица, обеспечивающая пролонгированное, инвариантное и независимое высвобождение активных соединений
RU2006128796/15A RU2342935C2 (ru) 2002-04-05 2006-08-08 Фармацевтическая композиция для лечения вызываемых опиоидами побочных эффектов и идиопатических синдромов

Country Status (33)

Country Link
US (11) US20050245556A1 (ru)
EP (17) EP2311438A1 (ru)
JP (5) JP4755810B2 (ru)
KR (3) KR100717591B1 (ru)
CN (4) CN102813654A (ru)
AP (2) AP2043A (ru)
AR (3) AR039378A1 (ru)
AT (1) ATE418967T2 (ru)
AU (2) AU2003224040B2 (ru)
BR (2) BR0309004A (ru)
CA (3) CA2708900C (ru)
CO (2) CO5611100A2 (ru)
CY (5) CY1108914T1 (ru)
DE (6) DE20308437U1 (ru)
DK (6) DK1492506T4 (ru)
ES (7) ES2546010T3 (ru)
FI (1) FI7846U1 (ru)
GE (3) GEP20074022B (ru)
HK (5) HK1072367A1 (ru)
HU (4) HUE027004T2 (ru)
IL (5) IL163990A0 (ru)
LT (3) LT2425825T (ru)
MA (2) MA27249A1 (ru)
MX (2) MXPA04009714A (ru)
NZ (1) NZ535286A (ru)
PH (1) PH12018000176A1 (ru)
PT (5) PT1492506E (ru)
RU (3) RU2295344C2 (ru)
SI (5) SI2425825T1 (ru)
TN (1) TNSN04192A1 (ru)
TW (3) TWI345973B (ru)
WO (2) WO2003084504A2 (ru)
ZA (2) ZA200407267B (ru)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
UA55507C2 (ru) 1997-12-22 2003-04-15 Еро-Селтік, С.А. Комбинации агонист / антагонист опиоида
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN1407884B (zh) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
CA2400567C (en) 2000-02-08 2008-01-15 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1416842B1 (en) 2001-07-18 2008-12-31 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
PT1414451E (pt) 2001-08-06 2009-07-31 Euro Celtique Sa Formulações agonistas de opióides com antagonista libertável e sequestrado
TWI345973B (en) 2002-04-05 2011-08-01 Euro Celtique Sa Matrix for sustained, invariant and independent release of active compounds
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8679533B2 (en) 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE602004026604D1 (de) * 2003-09-25 2010-05-27 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP4971159B2 (ja) 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
BRPI0513847A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
AP2274A (en) * 2005-01-28 2011-08-19 Euro Celtiques Sa Alcohol resistant dosage forms.
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
AU2011202866B2 (en) * 2006-01-27 2012-06-14 Mundipharma Pty Limited Tamper resistant dosage forms
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CN101801350A (zh) * 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 抗滥用药物、使用方法和制备方法
RU2007137044A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
SI2273983T1 (sl) 2008-05-09 2016-11-30 Gruenenthal Gmbh Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
PT2317991T (pt) * 2008-07-07 2017-08-03 Euro Celtique Sa Utilização de antagonistas de opióides para tratar a retenção urinária
US9192578B2 (en) * 2008-08-20 2015-11-24 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
DK2352494T3 (da) 2008-10-30 2019-10-28 Gruenenthal Gmbh Nye og potente tapentadoldoseringsformer
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
EP2405915B1 (en) 2009-03-10 2018-10-24 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533586A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
WO2011141489A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
EP2568965A1 (en) 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CN105832687A (zh) 2010-05-10 2016-08-10 欧洲凯尔特公司 包含氢吗啡酮和纳洛酮的药物组合物
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
KR102435108B1 (ko) 2010-08-04 2022-08-22 핀치 테라퓨틱스 홀딩스 엘엘씨 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
JP6007176B2 (ja) * 2010-08-13 2016-10-12 ユーロ−セルティーク エス．エイ． 保存に安定な製剤を製造するための結合剤の使用
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
NZ609874A (en) * 2010-09-30 2014-10-31 Astrazeneca Ab Crystalline naloxol-peg conjugate
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
EA025261B1 (ru) * 2011-08-29 2016-12-30 Ксплор Инструментс Б.В. Лабораторный экструдер
CN103998025A (zh) * 2011-10-06 2014-08-20 格吕伦塔尔有限公司 包含阿片样物质激动剂和阿片样物质拮抗剂的防篡改口服药物剂型
EP2780000B1 (en) 2011-11-17 2019-04-03 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PE20150020A1 (es) 2012-04-17 2015-01-28 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2854852A4 (en) 2012-06-04 2016-04-13 Centre For Digestive Diseases Pty Ltd COMPOSITIONS AND METHODS OF TREATING MORBUS CROHN AND RELATED DISEASES AND INFECTIONS
RU2015106688A (ru) 2012-07-27 2016-09-20 Редхилл Байофарма Лтд. Препараты и способы получения препаратов для применения при опорожнении толстой кишки
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
ES2984559T3 (es) * 2012-12-14 2024-10-29 Trevi Therapeutics Inc Métodos de tratamiento del prurito
EP2976082A4 (en) 2013-03-15 2016-05-11 Inspirion Delivery Technologies Llc MISS-INFANT COMPOSITIONS AND METHODS OF USE
WO2014176632A1 (en) 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US20160244459A1 (en) 2013-05-24 2016-08-25 Rhodes Technologies Opioid ketal compounds and uses thereof
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
BR112016009749A8 (pt) 2013-11-13 2018-01-30 Euro Celtique Sa hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
US9456986B2 (en) 2013-12-11 2016-10-04 Develco Pharma Schweiz Ag Naloxone mono preparation and multilayer tablet
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016091805A2 (de) * 2014-12-08 2016-06-16 Develco Pharma Schweiz Ag Naloxon-monopräparat und mehrschichttablette
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
KR20180026376A (ko) 2015-05-14 2018-03-12 크레스토보 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
ES2909456T3 (es) 2015-05-22 2022-05-06 Univ Arizona State Métodos para tratar el trastorno del espectro autista y síntomas asociados
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
EP3352773A4 (en) 2015-09-24 2019-03-27 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation ANTIBACTERIAL AND PROTECTIVE BACTERIOPHAGE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
AU2017241266B2 (en) 2016-03-31 2022-02-10 SpecGx LLC Extended release, abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3290027A1 (en) * 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018313766A1 (en) 2017-08-07 2020-02-20 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019152002A1 (en) * 2018-01-31 2019-08-08 Dharma Laboratories LLC Non-extractable oral solid dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
WO2019165298A1 (en) 2018-02-23 2019-08-29 Rhodes Technologies Novel opioid compounds and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US20200022974A1 (en) 2018-07-23 2020-01-23 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
JP2022514145A (ja) 2018-09-27 2022-02-10 フィンチ セラピューティクス ホールディングス エルエルシー てんかんおよび関連する障害を治療するための組成物および方法
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3173877A (en) 1957-09-09 1965-03-16 Wyandotte Chemicals Corp Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (ru) * 1960-11-29
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (ru) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) * 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
FR2183546B1 (ru) * 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
LU77339A1 (ru) 1977-05-16 1979-01-19
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE3434946A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
ZA861211B (en) 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition
JPS61280423A (ja) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
WO1987001282A2 (en) 1985-09-06 1987-03-12 Key Pharmaceuticals, Inc. Method and composition for providing sustained opioid antagonism
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (es) 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
JP3178541B2 (ja) 1991-05-29 2001-06-18 キヤノン株式会社 画像処理方法及び装置
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
AU651247B2 (en) 1991-09-06 1994-07-14 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
NZ254404A (en) 1992-06-22 1997-08-22 Univ California Substituted 1,4-dihydroquinoxaline-2,3-diones and pharmaceutical compositions thereof
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
JPH08504189A (ja) 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
NZ260883A (en) 1993-07-01 1997-06-24 Euro Celtique Sa Oral sustained-release medicaments containing morphine
CN1230154C (zh) * 1993-07-01 2005-12-07 欧洲凯尔特公司 缓释组合物及制备药用组合物的方法
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
EP0654263B1 (en) 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0799051B1 (en) 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5692500A (en) 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
CA2239301A1 (en) 1995-12-06 1997-06-12 Charles Howard Mitch Composition for treating pain
CN100475210C (zh) 1996-03-08 2009-04-08 尼科梅德丹麦有限公司 改进释放的多单位剂量组合物
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
JPH11508608A (ja) * 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998024412A2 (en) * 1996-12-05 1998-06-11 The Board Of Trustees Of The University Of Illinois Compounds useful against diseases of the colon and methods for orally administering same
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
ES2141631T3 (es) 1997-02-14 2000-03-16 Goedecke Ag Estabilizacion del hidrocloruro de naloxon.
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
DE69834195T2 (de) 1997-07-02 2007-03-29 Euro-Celtique S.A. Stabilisierte tramadol formulierungen mit verzögerter freisetzung
WO1999005960A1 (en) 1997-07-30 1999-02-11 Universite De Montreal Portable and programmable interactive visual analogue scale data-logger device
ES2395268T3 (es) 1997-09-04 2013-02-11 Demerx, Inc. Noribogaína para el tratamiento del dolor y la drogadicción
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
UA55507C2 (ru) * 1997-12-22 2003-04-15 Еро-Селтік, С.А. Комбинации агонист / антагонист опиоида
PL343593A1 (en) * 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
US5957459A (en) 1998-04-27 1999-09-28 Chae; Myung Joo Banking card game
DE19857766A1 (de) 1998-05-28 1999-12-02 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin
ATE261302T1 (de) 1998-05-28 2004-03-15 Krewel Meuselbach Gmbh Retardiertes schmerzmittel enthaltend tilidin
DE29818454U1 (de) 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
SE9803760D0 (sv) 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
DE19859636A1 (de) * 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
DE19901085C2 (de) 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US6419595B1 (en) 1999-07-09 2002-07-16 Bridgestone Sports Co., Ltd. Solid golf ball
US6451007B1 (en) 1999-07-29 2002-09-17 Dale E. Koop Thermal quenching of tissue
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
JP2003513045A (ja) * 1999-11-01 2003-04-08 ロデバ・リミテッド 便秘及び過敏性大腸症候群を治療・処置するための組成物
DE60032940T2 (de) 1999-11-29 2007-11-08 Adolor Corp. Neue verfahren und zubereitungen die opioiden und deren antagonisten enthalten
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CA2400567C (en) * 2000-02-08 2008-01-15 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CA2403252A1 (en) 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
JP2004501094A (ja) 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法
WO2001093852A2 (en) 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
JP4121858B2 (ja) * 2001-04-19 2008-07-23 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 縮合した二環式又は三環式アミノ酸
UA81224C2 (ru) 2001-05-02 2007-12-25 Euro Celtic S A Дозированная форма оксикодона и ее применение
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030004177A1 (en) 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DE10131113A1 (de) 2001-06-28 2003-01-23 Siemens Linear Motor Systems G Rotations-Elektromotor
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
EP1416842B1 (en) * 2001-07-18 2008-12-31 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
CA2456322A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
DE20220917U1 (de) 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
PT1414451E (pt) 2001-08-06 2009-07-31 Euro Celtique Sa Formulações agonistas de opióides com antagonista libertável e sequestrado
AU2002339395A1 (en) 2001-09-06 2003-03-18 Hans Gregersen Method an apparatus for stimulating a bodily hollow system and method and apparatus for measuring reactions to stimuli of such system
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002336765B2 (en) 2001-09-24 2007-12-20 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
PT1482835E (pt) 2002-03-06 2012-12-26 Euro Celtique Sa Escala analógica para medição da dor
CA2748620C (en) 2002-03-14 2014-03-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
TWI345973B (en) 2002-04-05 2011-08-01 Euro Celtique Sa Matrix for sustained, invariant and independent release of active compounds
DE10215067A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
DE10215131A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
AU2003247876B2 (en) * 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
RU2222260C1 (ru) 2002-07-08 2004-01-27 Сибирский государственный медицинский университет Способ дифференцированной оценки степени функциональной активности тонкой кишки
JP5189242B2 (ja) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
CN100500130C (zh) 2003-01-23 2009-06-17 株式会社太平洋 缓释制剂及其制备方法
WO2004091623A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AP2274A (en) 2005-01-28 2011-08-19 Euro Celtiques Sa Alcohol resistant dosage forms.
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070092576A1 (en) 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2007111945A2 (en) 2006-03-22 2007-10-04 Trustees Of Boston University Method for management of diarrhea
EP2012790A4 (en) 2006-04-19 2009-07-01 Smith Jill P TREATMENT OF INFLAMMATORY AND ULCEROUS DISEASES OF THE COLON USING OPIOID ANTAGONISTS
DE202006018609U1 (de) 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2042176A1 (en) 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
PT2317991T (pt) 2008-07-07 2017-08-03 Euro Celtique Sa Utilização de antagonistas de opióides para tratar a retenção urinária
EP2405915B1 (en) 2009-03-10 2018-10-24 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NO330672B1 (no) 2009-11-12 2011-06-06 Proxdynamics As Rotormekanisme for helikoptere
JP6007176B2 (ja) 2010-08-13 2016-10-12 ユーロ−セルティーク エス．エイ． 保存に安定な製剤を製造するための結合剤の使用

Also Published As

Publication number Publication date
TWI337077B (en) 2011-02-11
ZA200407317B (en) 2005-08-31
HUE027004T2 (en) 2016-08-29
US20180214443A1 (en) 2018-08-02
RU2297225C2 (ru) 2007-04-20
EP2425824A1 (en) 2012-03-07
AP2004003138A0 (en) 2004-09-30
US9555000B2 (en) 2017-01-31
CY1118921T1 (el) 2018-01-10
SI2425821T1 (sl) 2017-06-30
DK1492506T4 (en) 2016-10-03
EP2425821A1 (en) 2012-03-07
FIU20070322U0 (fi) 2007-08-17
EP2316428A1 (en) 2011-05-04
EP1492505B1 (en) 2015-06-03
US20120108621A1 (en) 2012-05-03
BR0309544A (pt) 2005-02-01
ES2320748T5 (es) 2017-02-20
ES2627300T3 (es) 2017-07-27
US8846090B2 (en) 2014-09-30
TWI345973B (en) 2011-08-01
MXPA04009713A (es) 2005-01-11
US10420762B2 (en) 2019-09-24
TNSN04192A1 (fr) 2007-03-12
JP2005529097A (ja) 2005-09-29
MA27249A1 (fr) 2005-03-01
FI7846U1 (fi) 2008-04-28
LT2425824T (lt) 2017-07-25
PT2425821T (pt) 2017-08-23
CY1119120T1 (el) 2018-02-14
DE20308437U1 (de) 2003-11-13
SI1492505T1 (sl) 2015-10-30
CN107669681A (zh) 2018-02-09
BRPI0309544B8 (pt) 2021-05-25
GEP20064022B (en) 2007-01-10
IL200621A (en) 2016-02-29
EP2308474A1 (en) 2011-04-13
HK1072367A1 (en) 2005-08-26
AR039378A1 (es) 2005-02-16
AP2043A (en) 2009-09-09
EP2316429A1 (en) 2011-05-04
US20150005335A1 (en) 2015-01-01
DK2425825T3 (en) 2017-02-20
US20140045877A1 (en) 2014-02-13
JP2010180233A (ja) 2010-08-19
EP3241548A1 (en) 2017-11-08
PT2425825T (pt) 2017-02-13
EP2425823A1 (en) 2012-03-07
KR20070006945A (ko) 2007-01-11
IL163990A0 (en) 2005-12-18
HUE032529T2 (en) 2017-09-28
ES2320748T3 (es) 2009-05-28
US9655855B2 (en) 2017-05-23
PT1492505E (pt) 2015-10-06
NZ535286A (en) 2007-07-27
WO2003084504A2 (en) 2003-10-16
DK200700243U3 (da) 2008-01-25
US20050245556A1 (en) 2005-11-03
CN1646102A (zh) 2005-07-27
RU2006128796A (ru) 2008-02-20
JP4620355B2 (ja) 2011-01-26
DE60325567D1 (de) 2009-02-12
EP2425825B9 (en) 2017-03-01
US20170112828A1 (en) 2017-04-27
MXPA04009714A (es) 2005-12-05
US20050245483A1 (en) 2005-11-03
US20120183612A1 (en) 2012-07-19
PH12018000176A1 (en) 2018-11-19
HK1072366A1 (en) 2005-08-26
RU2004130845A (ru) 2005-06-10
SI1492506T1 (sl) 2009-04-30
US20140045878A1 (en) 2014-02-13
US20140296277A1 (en) 2014-10-02
AU2003224040B2 (en) 2006-06-22
EP2425825A1 (en) 2012-03-07
EP2311438A1 (en) 2011-04-20
DE20308436U1 (de) 2003-09-18
TWI334779B (en) 2010-12-21
CA2478515C (en) 2010-09-28
KR100784341B1 (ko) 2007-12-13
CY1116640T1 (el) 2017-03-15
WO2003084520A2 (en) 2003-10-16
EP1639996A1 (en) 2006-03-29
EP1492506B2 (en) 2016-06-29
AU2003224041B2 (en) 2006-07-13
DK2425821T5 (en) 2018-02-12
CA2478515A1 (en) 2003-10-16
HK1254279A1 (zh) 2019-07-19
EP2425821B1 (en) 2017-05-10
DK2425824T3 (en) 2017-08-28
AP2004003137A0 (en) 2004-09-30
CN1642529A (zh) 2005-07-20
LT2425821T (lt) 2017-07-25
JP2014129397A (ja) 2014-07-10
JP5107954B2 (ja) 2012-12-26
IL182742A0 (ru) 2007-07-24
US9907793B2 (en) 2018-03-06
US8846091B2 (en) 2014-09-30
DE17154462T1 (de) 2019-12-19
HUE032656T2 (en) 2017-10-30
AP2397A (en) 2012-04-23
DK1492505T3 (en) 2015-08-10
ES2608006T3 (es) 2017-04-05
KR20040098050A (ko) 2004-11-18
EP2425825B1 (en) 2016-11-16
AU2003224041A1 (en) 2003-10-20
WO2003084504A3 (en) 2004-03-11
JP5932209B2 (ja) 2016-06-08
PT1492506E (pt) 2009-03-16
EP3326618A1 (en) 2018-05-30
KR100717591B1 (ko) 2007-05-15
ES2733044T1 (es) 2019-11-27
EP1492506A2 (en) 2005-01-05
GEP20074022B (en) 2007-01-10
ZA200407267B (en) 2005-08-31
ES2546010T3 (es) 2015-09-17
ATE418967T2 (de) 2009-01-15
SI2425825T1 (sl) 2017-05-31
AR090677A2 (es) 2014-11-26
HK1246176A1 (zh) 2018-09-07
JP2005528375A (ja) 2005-09-22
PT2425824T (pt) 2017-08-23
AU2003224040A1 (en) 2003-10-20
AR039379A1 (es) 2005-02-16
DK2425824T5 (en) 2018-02-12
DK2425821T3 (en) 2017-08-28
EP2425824B1 (en) 2017-05-10
HK1166463A1 (zh) 2012-11-02
IL163989A0 (en) 2005-12-18
IL200621A0 (en) 2011-07-31
JP4755810B2 (ja) 2011-08-24
SI2425824T1 (sl) 2017-06-30
CO5611093A2 (es) 2006-02-28
CY1119168T1 (el) 2018-02-14
CY1108914T1 (el) 2014-07-02
EP2243471A1 (en) 2010-10-27
TW200403996A (en) 2004-03-16
DK1492506T3 (da) 2009-03-16
CA2478523A1 (en) 2003-10-16
IL163990A (en) 2010-04-29
LT2425825T (lt) 2017-02-27
JP2009167198A (ja) 2009-07-30
CN1646102B (zh) 2012-08-15
EP1492505A2 (en) 2005-01-05
WO2003084520A3 (en) 2004-03-11
HUE031668T2 (en) 2017-07-28
DE20321531U1 (de) 2007-11-22
KR20040098052A (ko) 2004-11-18
CA2708900C (en) 2019-06-04
DK200700243U1 (da) 2007-11-09
TW200716113A (en) 2007-05-01
EP2319496A1 (en) 2011-05-11
EP1639997A1 (en) 2006-03-29
CN102813654A (zh) 2012-12-12
EP2308475A1 (en) 2011-04-13
BR0309004A (pt) 2005-02-01
TW200408394A (en) 2004-06-01
GEP20084485B (en) 2008-09-25
BRPI0309544B1 (pt) 2018-04-03
CN100411611C (zh) 2008-08-20
ES2627298T3 (es) 2017-07-27
MA27116A1 (fr) 2004-12-20
CO5611100A2 (es) 2006-02-28
CA2708900A1 (en) 2003-10-16
ES2733051T1 (es) 2019-11-27
RU2342935C2 (ru) 2009-01-10
RU2295344C2 (ru) 2007-03-20
DE17169621T1 (de) 2019-12-19
US20170231978A1 (en) 2017-08-17
EP1492506B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
RU2004131870A (ru) Фармацевтический препарат, содержащий оксикодон и налоксон
ES2393640T3 (es) Comprimidos bucodisgregables
JP7148498B2 (ja) （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの製剤
US5200193A (en) Pharmaceutical sustained release matrix and process
US5529783A (en) Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
JP4832045B2 (ja) メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物
BRPI0714514A2 (pt) grÂnulo e comprimido para desintegraÇço oral compreendendo oxicodona
FI117373B (fi) Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
NZ236834A (en) Oral medicaments comprising pimobendan in dry mixture with citric acid
JPWO2011071139A1 (ja) 有核型の口腔内崩壊錠
JP7127832B2 (ja) マジンドールのｉｒ／ｓｒ多層錠剤及び該錠剤の注意欠陥／多動性障害（ａｄｈｄ）の治療のための使用
US3524910A (en) Sustained relief analgesic compositions
US7993673B2 (en) Swallow tablet comprising paracetamol
CN109152841A (zh) N-炔丙胺衍生物的药物组合物
US6752997B2 (en) Process for preparing non-hygroscopic sodium valproate composition
JP2019019113A (ja) メマンチン塩酸塩含有口腔内崩壊錠
KR20160012706A (ko) 서방성 제제
RU2686694C2 (ru) Комбинированный лекарственный препарат в форме шипучих таблеток и способ его получения
KR20160030093A (ko) 구강 내 붕괴정
CA3008386C (en) Pharmaceutical composition comprising pimobendan
JP6106359B2 (ja) ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
WO2003075919A1 (fr) Comprime contenant du chlorhydrate de pilsicainide (voie seche)
JP5226732B2 (ja) 催眠用圧縮成型製剤
JP6271802B1 (ja) 口腔内崩壊錠
RU2276982C2 (ru) Средство, обладающее противовоспалительным, анальгетическим, жаропонижающим действием в форме таблетки